Selective Inhibition of Bruton’s Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Sousa, Bárbara B.; de Almeida, Cátia Rebelo; Barahona, Ana F.; Lopes, Raquel; Martins-Logrado, Ana; Cavaco, Marco; Neves, Vera; Carvalho, Luís A.R.; Labaõ-Almeida, Carlos; Coelho, Ana R.; Bento, Marta Leal; Lopes, Ricardo M.R.M.; Oliveira, Bruno L.; Castanho, Miguel A.R.B.; Neumeister, Peter; Deutsch, Alexander Vladimer, Gregory I.; Krall, Nikolaus; Joaõ, Cristina; Corzana, Francisco; Seixas,

Journal title: ACS Pharmacol. Transl. Sci

Journal publisher: ACS

Published year: 2022

DOI identifier: 10.1021/acsptsci.2c00163

ISSN: 2575-9108